Cargando…
Mental Health in Persons With Chronic Myeloid Leukemia During the SARS-CoV-2 Pandemic: The Need for Increased Access to Health Care Services
Mental health problems in the general population have been reported during the SARS-CoV-2 pandemic; however, there were rare data in persons with chronic myeloid leukemia (CML). Therefore, we performed a cross-sectional study on mental health evaluated using the 9-item Patient Health Questionnaire (...
Autores principales: | Bao, Mei, Yang, Sen, Gale, Robert Peter, Zhang, Yanli, Liu, Xiaoli, Zhu, Huanling, Liang, Rong, Liu, Bingcheng, Zhou, Li, Li, Zongru, Dou, Xuelin, Shi, Dayu, Wang, Tao, Meng, Li, Li, Weiming, Jiang, Qian |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8217438/ https://www.ncbi.nlm.nih.gov/pubmed/34168583 http://dx.doi.org/10.3389/fpsyt.2021.679932 |
Ejemplares similares
-
Safety of SARS-CoV-2 vaccines in patients with chronic myeloid leukemia: a multicenter survey in China
por: Yang, Yunfan, et al.
Publicado: (2022) -
Quality‐of‐life, mental health, and perspective on TKI dose reduction as a prelude to discontinuation in chronic phase chronic myeloid leukemia
por: Chen, Yilin, et al.
Publicado: (2023) -
Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2 trial
por: Jiang, Qian, et al.
Publicado: (2022) -
Correction: Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2 trial
por: Jiang, Qian, et al.
Publicado: (2022) -
Correction: Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2 trial
por: Jiang, Qian, et al.
Publicado: (2023)